Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Short term Debt (2020 - 2024)

Historic Short term Debt for Syndax Pharmaceuticals (SNDX) over the last 5 years, with Q4 2024 value amounting to $12.1 million.

  • Syndax Pharmaceuticals' Short term Debt changed N/A to $12.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $12.1 million, marking a year-over-year change of. This contributed to the annual value of $12.1 million for FY2024, which is N/A changed from last year.
  • Syndax Pharmaceuticals' Short term Debt amounted to $12.1 million in Q4 2024.
  • Syndax Pharmaceuticals' Short term Debt's 5-year high stood at $12.1 million during Q4 2024, with a 5-year trough of $187000.0 in Q4 2021.
  • Moreover, its 4-year median value for Short term Debt was $5.8 million (2021), whereas its average is $5.8 million.
  • Its Short term Debt has fluctuated over the past 5 years, first crashed by 9181.62% in 2021, then skyrocketed by 258.89% in 2022.
  • Over the past 4 years, Syndax Pharmaceuticals' Short term Debt (Quarter) stood at $2.3 million in 2020, then tumbled by 91.82% to $187000.0 in 2021, then skyrocketed by 3756.68% to $7.2 million in 2022, then skyrocketed by 68.0% to $12.1 million in 2024.
  • Its last three reported values are $12.1 million in Q4 2024, $7.2 million for Q2 2022, and $3.6 million during Q1 2022.